Caroline Liu1, Neha Debnath2, Gohar Mosoyan3, Kinsuk Chauhan3, George Vasquez-Rios3, Celine Soudant4, Steve Menez5, Chirag R Parikh5, Steven G Coca6. 1. Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Department of Medicine, Icahn School of Medicine at Mount Sinai (Morningside/West), New York, New York. 3. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Division of Technology, Memorial Sloan Kettering Cancer Center Medical Library, New York, New York. 5. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York steven.coca@mssm.edu.
Abstract
BACKGROUND: Sensitive and specific biomarkers are needed to provide better biologic insight into the risk of incident and progressive CKD. However, studies have been limited by sample size and design heterogeneity. METHODS: In this assessment of the prognostic value of preclinical plasma and urine biomarkers for CKD outcomes, we searched Embase (Ovid), MEDLINE ALL (Ovid), and Scopus up to November 30, 2020, for studies exploring the association between baseline kidney biomarkers and CKD outcomes (incident CKD, CKD progression, or incident ESKD). We used random-effects meta-analysis. RESULTS: After screening 26,456 abstracts and 352 full-text articles, we included 129 studies in the meta-analysis for the most frequently studied plasma biomarkers (TNFR1, FGF23, TNFR2, KIM-1, suPAR, and others) and urine biomarkers (KIM-1, NGAL, and others). For the most frequently studied plasma biomarkers, pooled RRs for CKD outcomes were 2.17 (95% confidence interval [95% CI], 1.91 to 2.47) for TNFR1 (31 studies); 1.21 (95% CI, 1.15 to 1.28) for FGF-23 (30 studies); 2.07 (95% CI, 1.82 to 2.34) for TNFR2 (23 studies); 1.51 (95% CI, 1.38 to 1.66) for KIM-1 (18 studies); and 1.42 (95% CI, 1.30 to 1.55) for suPAR (12 studies). For the most frequently studied urine biomarkers, pooled RRs were 1.10 (95% CI, 1.05 to 1.16) for KIM-1 (19 studies) and 1.12 (95% CI, 1.06 to 1.19) for NGAL (19 studies). CONCLUSIONS: Studies of preclinical biomarkers for CKD outcomes have considerable heterogeneity across study cohorts and designs, limiting comparisons of prognostic performance across studies. Plasma TNFR1, FGF23, TNFR2, KIM-1, and suPAR were among the most frequently investigated in the setting of CKD outcomes.
BACKGROUND: Sensitive and specific biomarkers are needed to provide better biologic insight into the risk of incident and progressive CKD. However, studies have been limited by sample size and design heterogeneity. METHODS: In this assessment of the prognostic value of preclinical plasma and urine biomarkers for CKD outcomes, we searched Embase (Ovid), MEDLINE ALL (Ovid), and Scopus up to November 30, 2020, for studies exploring the association between baseline kidney biomarkers and CKD outcomes (incident CKD, CKD progression, or incident ESKD). We used random-effects meta-analysis. RESULTS: After screening 26,456 abstracts and 352 full-text articles, we included 129 studies in the meta-analysis for the most frequently studied plasma biomarkers (TNFR1, FGF23, TNFR2, KIM-1, suPAR, and others) and urine biomarkers (KIM-1, NGAL, and others). For the most frequently studied plasma biomarkers, pooled RRs for CKD outcomes were 2.17 (95% confidence interval [95% CI], 1.91 to 2.47) for TNFR1 (31 studies); 1.21 (95% CI, 1.15 to 1.28) for FGF-23 (30 studies); 2.07 (95% CI, 1.82 to 2.34) for TNFR2 (23 studies); 1.51 (95% CI, 1.38 to 1.66) for KIM-1 (18 studies); and 1.42 (95% CI, 1.30 to 1.55) for suPAR (12 studies). For the most frequently studied urine biomarkers, pooled RRs were 1.10 (95% CI, 1.05 to 1.16) for KIM-1 (19 studies) and 1.12 (95% CI, 1.06 to 1.19) for NGAL (19 studies). CONCLUSIONS: Studies of preclinical biomarkers for CKD outcomes have considerable heterogeneity across study cohorts and designs, limiting comparisons of prognostic performance across studies. Plasma TNFR1, FGF23, TNFR2, KIM-1, and suPAR were among the most frequently investigated in the setting of CKD outcomes.
Authors: Tomohito Gohda; Monika A Niewczas; Linda H Ficociello; William H Walker; Jan Skupien; Florencia Rosetti; Xavier Cullere; Amanda C Johnson; Gordon Crabtree; Adam M Smiles; Tanya N Mayadas; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2012-01-19 Impact factor: 10.121
Authors: Monika A Niewczas; Tomohito Gohda; Jan Skupien; Adam M Smiles; William H Walker; Florencia Rosetti; Xavier Cullere; John H Eckfeldt; Alessandro Doria; Tanya N Mayadas; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2012-01-19 Impact factor: 10.121
Authors: Meredith C Foster; Josef Coresh; Joseph V Bonventre; Venkata S Sabbisetti; Sushrut S Waikar; Theodore E Mifflin; Robert G Nelson; Morgan Grams; Harold I Feldman; Ramachandran S Vasan; Paul L Kimmel; Chi-Yuan Hsu; Kathleen D Liu Journal: Clin J Am Soc Nephrol Date: 2015-09-08 Impact factor: 8.237
Authors: Changli Wei; Clemens C Möller; Mehmet M Altintas; Jing Li; Karin Schwarz; Serena Zacchigna; Liang Xie; Anna Henger; Holger Schmid; Maria P Rastaldi; Peter Cowan; Matthias Kretzler; Roberto Parrilla; Moïse Bendayan; Vineet Gupta; Boris Nikolic; Raghu Kalluri; Peter Carmeliet; Peter Mundel; Jochen Reiser Journal: Nat Med Date: 2007-12-16 Impact factor: 53.440
Authors: Taha Sen; Jingwei Li; Brendon L Neuen; Bruce Neal; Clare Arnott; Chirag R Parikh; Steven G Coca; Vlado Perkovic; Kenneth W Mahaffey; Yshai Yavin; Norman Rosenthal; Michael K Hansen; Hiddo J L Heerspink Journal: Diabetologia Date: 2021-08-20 Impact factor: 10.122
Authors: Sarah J Schrauben; Haochang Shou; Xiaoming Zhang; Amanda Hyre Anderson; Joseph V Bonventre; Jing Chen; Steven Coca; Susan L Furth; Jason H Greenberg; Orlando M Gutierrez; Joachim H Ix; James P Lash; Chirag R Parikh; Casey M Rebholz; Venkata Sabbisetti; Mark J Sarnak; Michael G Shlipak; Sushrut S Waikar; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Jeffrey R Schelling Journal: J Am Soc Nephrol Date: 2020-10-29 Impact factor: 14.978